Navigation Links
HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
Date:10/1/2007

SAN DIEGO and SHANGHAI, China, Oct. 2 /PRNewswire/ -- HUYA Bioscience International (HUYA), a rapidly expanding biopharmaceutical company focused on the development of key disease-fighting drugs sourced from China, announced today that it has licensed a novel clinical stage anti-arrhythmic compound from the prestigious Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences.

The compound, HBI-3000 or sulcardine, exhibits a unique profile of myocardial ion channel regulation, compared to approved US and European anti- arrhythmic therapeutics. HBI-3000 has met significant Phase I safety milestones in three completed studies under a SIMM-sponsored Chinese IND. Gary T. Elliott, Pharm.D., Ph.D., Executive Vice President of Product Development at HUYA, commented that "the compound displays an ion channel selectivity profile that may contribute to effective treatment of both ventricular and atrial arrhythmias, while decreasing the risk of sudden death (Torsade de Pointes) associated with some anti-arrhythmics currently on the market."

Mireille Gingras, Ph.D., CEO of HUYA said, "There is a large unmet medical need for safer and more effective treatments for atrial and ventricular arrhythmia. We believe that HBI-3000 has the potential to fill this need, based on its unique properties and significant performance to date. By 2015, the global anti-arrhythmic market is expected to be $3.5 billion, and we feel we are on target to provide an innovative product."

Additional information is available at http://www.huyabio.com.

ABOUT HUYA

HUYA Bioscience International, LLC, with offices in San Diego and Shanghai, capitalizes on the explosive growth of the biotechnology and pharmaceutical industries in China. HUYA identifies and licenses promising Chinese pharmaceuticals for development and commercialization in Western markets. Using its management team and advisors, HUYA lowers the
'/>"/>

SOURCE HUYA Bioscience International, LLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Bioscience clusters: Too many or room for more?
5. Quintessence Biosciences names new president
6. Caden Biosciences may signal critical mass
7. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
8. WARF signs licensing pact with BD Biosciences
9. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
10. Bioscience beats beer
11. State awards QRG Biosciences development grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 WriteResult, LLC – a premier ... again shown superiority when it comes to meeting the ... ePRO portion of their most recent study closeout on-time ... chose WriteResult’s digital writing platform to collect Patient Reported ... to complete drew data from a number of assessments ...
(Date:8/26/2014)... , Aug. 26, 2014  NeuroSigma, Inc., a ... established to develop bioelectronic technologies, today announced that it ... the U.S. Securities and Exchange Commission relating to a ... number of shares to be offered and the price ... determined. Jefferies LLC will act as the ...
(Date:8/26/2014)... 2014 The 20 ambassadors representing the ... community issued the following statement on Facebook today regarding ... driving new funding specifically for ALS research: , “Who ... some ice would raise all this awareness and funding ... and on behalf of the entire ALS community, would ...
(Date:8/26/2014)... REHOVOT, Israel , August 26, 2014 /PRNewswire/ ... specialist, Replica 3DM, supports NHS hospitals with surgery validation using ... - Performing surgery on 3D printed models ... patient recovery and provides an effective aid for both patient ... (Nasdaq: SSYS ), a global leader of 3D ...
Breaking Biology Technology:A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5
... DIEGO, April 9, 2008 ADVENTRX,Pharmaceuticals, Inc. (Amex: ... appointed,Jose Hechavarria to the new position of vice ... leading the company,s planned,commercial manufacturing operations., "We ... team," said Evan M.,Levine, ADVENTRX chief executive officer. ...
... future ... sales ... LOR; AMEX: LRP), a biopharmaceutical company dedicated to,the research and development ... that its subsidiary GeneSense,Technologies, Inc. ("GeneSense") has signed an exclusive multinational,license ...
... Inc. (Nasdaq: TPPH ) today announced that ... Market ("Nasdaq") formally notifying it that,Nasdaq has not ... January,2, 2008, as required by Marketplace Rule 4310(c)(14) ... will be suspended. Tapestry,does not intend to appeal ...
Cached Biology Technology:ADVENTRX Appoints Vice President of Manufacturing 2ADVENTRX Appoints Vice President of Manufacturing 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 2Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 5Tapestry Receives Nasdaq Delisting Notice 2
(Date:8/27/2014)... evidence puts into doubt the long-standing belief that a ... brain plays a central role in depression. In ... that mice lacking the ability to make serotonin in ... conventional wisdom) did not show depression-like symptoms. , ... VA Medical Center and Wayne State University School of ...
(Date:8/27/2014)... number of studies have shown that excessive ... of Parkinson,s disease. Previous studies from Chunyan ... in China have shown that baicalin prevented ... divalent metal transporter 1 expression, and increased ... of rotenone-induced Parkinson,s disease rats. However, the ...
(Date:8/27/2014)... Listeria is a dreaded bacterium that can be ... last few weeks, 28 persons in Denmark have been ... in supermarkets. 13 have died. , The bacterium is ... uncanny ability to adapt to changes in its surroundings, ... Together with colleagues from the Department of Biochemistry and ...
Breaking Biology News(10 mins):New study throws into question long-held belief about depression 2Researchers discover why Listeria bacterium is so hard to fight 2Researchers discover why Listeria bacterium is so hard to fight 3
... SAN DIEGO , May 11 ... Biomatrica Connect™, a solution-centric partnership program established with ... room temperature storage and management of nucleic acids. ... scientific/industry partnership for the development, testing, validation and ...
... commentary on the nature of pathogens is raising startling new ... plays in the understanding of emerging disease. Ecological speciation, and ... shifts onto a novel host, is one of the main ... argue the authors of a new paper published online in ...
... NY) A multi-institutional team of researchers, including scientists ... has received a prestigious National Institutes of Health (NIH) ... structure and function of unknown enzymes identified in genome-sequencing ... the metabolic and chemical diversity that exists in nature ...
Cached Biology News:Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 2Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 3Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 4Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 5Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 6Emergence of fungal plant diseases linked to ecological speciation 2NIH funds multicenter 'glue grant' to study enzyme function 2
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... With the macro- and micronutrients ... Skoog (1962) and the vitamins ... al. (1968). Preparation Quantity Equivalency: ... of powder per liter of ...
Biology Products: